期刊文献+

YKL-40蛋白检测在卵巢癌诊断中的应用 被引量:6

Application of YKL-40 protein detection in the diagnosis of ovarian cancer
下载PDF
导出
摘要 目的检测卵巢癌患者血清人软骨糖蛋白-39(YKL-40)及糖类抗原125(CA125)水平,以及卵巢癌组织YKL-40表达,探讨YKL-40蛋白检测在卵巢癌诊断中的应用。方法选择恶性卵巢癌患者17例,交界性卵巢肿瘤患者16例,以及良性卵巢肿瘤患者19例,另选取非卵巢癌对照患者20例,检测患者术前血清CA125水平及YKL-40水平,术后YKL-40水平,免疫组化检测卵巢组织YKL-40蛋白表达情况。结果术前血清YKL-40水平随肿瘤恶性程度增加而显著升高(P<0.05或P<0.01),卵巢癌患者手术前后YKL-40水平具有显著性差异(P<0.01)。随肿瘤恶性程度增加,肿瘤组织YKL-40表达量增加。YKL-40联合CA125检测诊断恶性卵巢癌的灵敏度显著高于单独检测其中之一。结论 YKL-40蛋白表达可作为卵巢癌的诊断标志物,血清YKL-40水平联合CA125水平检测可提高对卵巢癌诊断的灵敏度。 Objective To detect the serum levels of human cartilage glycoprotein-39( YKL-40) and carbohydrate antigen 125( CA125) and the expression of YKL-40 in patients with ovarian cancer so as to explore the application of YKL-40 protein detection in diagnosis of ovarian cancer.Methods A total of 17 patients with malignant ovarian cancer,16 pateitns with borderline ovarian cancer,19 patients with benign ovarian cancer and 20 patients with non-ovarian cancer were selected.The levels of serum CA125 and YKL-40 level before operation and YKL-40 level after operation were detected. Immunohistochemical method was used to detect TKL-40 protein expression in tissues of ovarian cancer. Results YKL-40 level increased along with the malignant severity of ovarian cancer before operation( P〈0. 05 or P〈0. 01),and there was significant difference of YKL-40 level before and after operation( P〈0. 01). The expression of YKL-40 in tumor tissue increased with the degree of malignancy deterioration. The sensitivity of YKL-40 combined with CA125 detection was significantly higher than that of YKL-40 or CA125 detection. Conclusion Expression of YKL-40 protein can be used as a diagnostic marker for ovarian cancer,and combined detection of YKL-40 and CA125 can improve the diagnostic sensitivity for patients with ovarian cancer.
出处 《实用临床医药杂志》 CAS 2015年第3期88-91,共4页 Journal of Clinical Medicine in Practice
关键词 人软骨糖蛋白-39 糖类抗原125 卵巢癌 免疫组织化学 human cartilage glycoprotein-39 carbohydrate antigen 125 ovarian cancer immunohistochemistry
  • 相关文献

参考文献18

  • 1Lim W,Song G.Discovery of prognostic factors for diagnosis and treatment of epithelial-derived ovarian cancer from laying hens[J].J Cancer Prev,2013,18(3):209.
  • 2Anastasi E,Marchei G G,Viggiani V,et al.HE4:a new potential early biomarker for the recurrence of ovarian cancer[J].Tumour Biol,2010,31(2):113.
  • 3Zou L,He X,Zhang J W.The efficacy of YKL-40 and CA125 as biomarkers for epithelial ovarian cancer[J].Braz J Med Biol Res,2010,43(12):1232.
  • 4刘国瑞,王艾丽,刘琦,经卉,李梅,严孝岭,虞伟,李晓军.联合检测血清CA125和HE4用于卵巢癌诊断及鉴别诊断[J].临床检验杂志,2010,28(2):119-121. 被引量:39
  • 5郝艳华,刘香萍,陈文萍,姚吉龙,程明刚.血清YKL-40和CA125联合检测在卵巢癌诊断中的应用[J].热带医学杂志,2009,9(1):42-45. 被引量:8
  • 6Yang S F,Wu T F,Tsai H T,et al.New markers in pelvic inflammatory disease[J].Clin Chim Acta,2014,431(1):118.
  • 7Vij R,Noth I.Peripheral blood biomarkers in idiopathic pulmonary fibrosis[J].Transl Res,2012,159(4):218.
  • 8Kastrup J.Can YKL-40 be a new inflammatory biomarker in cardiovascular disease[J].Immunobiology,2012,217(5):483.
  • 9Johansen J S,Jensen B V,Roslind A,et al.Serum YKL-40,a new prognostic biomarker incancer patients[J].Cancer Epidemiol Biomarkers Prey,2006,15(2):194.
  • 10Sarris E G,Syrigos K N,Saif M W.Pancreatic cancer:updates on translational research and future applications[J].Journal of the pancreas,2013,14(2):145.

二级参考文献58

  • 1蓝博文,谭秀钟,刘国荣,曾庆勇,曾裕镜,张磊.螺旋CT双期增强扫描对卵巢囊腺癌的诊断价值[J].热带医学杂志,2005,5(4):430-433. 被引量:5
  • 2陈洁晶,吴英松,宁云山,董文其,李明.卵巢癌肿瘤标记物HE4基因的分子克隆与蛋白表达[J].热带医学杂志,2006,6(5):493-495. 被引量:10
  • 3彭春杰,郑建华,刘运铎,徐柏.卵巢上皮性肿瘤中YKL-40的表达及意义[J].黑龙江医学,2007,31(7):483-485. 被引量:1
  • 4Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statiStics, 2001 [J]. CA Cancer J Clin, 2001,51 : 15-36.
  • 5Marsden DE, Friedlander M, Hacker NF. Current management of epithelial ovarian carcinoma : a rewiew [ R ]. Semin Surg Oncol, 2000, 19 ( 1 ) : 11-19.
  • 6Johansen JS, Williamson MK, Rice JS, et al. Identification of proteins secreted by human osteoblastic ceils in culture [J]. J Bone Miner Res, 1992,7(5):501-512.
  • 7Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39(CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation [ J ]. Genomics, 1997,43 (2) : 221- 225.
  • 8Diefenbach CS, Shah Z, Iasonos A, et al. Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer[ J ]. Gynecol Oncol, 2007,104 (2) : 435-442.
  • 9Dupont J, Tanwar MK, Thaler HT, et al. Early detection and prognosis of ovarian cancer using serum YKL-40 [J]. J Clin Oncol, 2004,22 (16) : 3330-3339.
  • 10Johansen JS, Jensen BV, Roslind A, et al. Serum YKL-40, a new prognostic biomarker in cancer patients [J]? Cancer Epidemiol Biomarkers Prey, 2006, 15(2) : 194-202.

共引文献72

同被引文献63

  • 1王清华,徐风亮,许祯杰.卵巢癌肿瘤分子标记物联合动态监测的研究与临床应用[J].中国临床实用医学,2014(4):24-26. 被引量:6
  • 2Fan JT, Si XH, Liao Y, et al. The diagnostic and prognostic value of serum YKL-40 in endometrial cancer[J]. Arch Gynecol Obstet, 2013, 287(1):111-115. DOI: 10.1007/ s00404-012-2546-5.
  • 3Francescone RA, Scully S, Faibish M, et al. Role of YKL-40 in the angiogenesis, radioresistance, and progression of gioblastoma[J]. J Biol Chem, 2011, 286(17):15332-15343. DOI: 10.1074/jbc.M110.212514.
  • 4Chiang YC, Lin HW, Chang CF, et al. Overexpression of CHI3L1 is associated with chemoresistance and poor outcome of epithelial ovarian carcinoma[J]. Oncotarget, 2015, 6(37): 39740-39755. DOI: 10.18632/oncotarget.5469.
  • 5Jordan SJ, Wilson LF, Nagle CM, et al. Cancers in Australia in 2010 attributable to and prevented by the use of menopausal hormone therapy[J]. Aust N Z J Public Health, 2015, 39(5):434-440. DOI: 10.1111/1753-6405.12451.
  • 6Myriokefalitaki E, Vorgias G, Vlahos G, et al. Prognostic value of preoperative Ca125 and Tag72 serum levels and their correlation to disease relapse and survival in endometrial cancer[J]. Arch Gynecol Obstet, 2015, 292(3):647-654. DOI: 10.1007/s00404-015 -3675 -4.
  • 7Antonsen SL, Hcgdall E, Christensen IJ, et al. HE4 and CA~25 levels in the preoperative assessment of endometrial cancer patients: a prospective multicenter study (ENDOMET)[J]. ActaObstet Gyneeol Stand, 2013, 9201):1313-1322. DOI: 10.1111/ aogs.12235.
  • 8Iwamoto FM, Hormigo A. Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma[J]. Front Oncol, 2014, 4:90. DOh 10.3389/font.2014.00090.
  • 9Johansen JS, Christensen IJ, Jcrgensen LN, et al. Serum YKL-40 in risk assessment for colorectal cancer: a prospective study of 4,496 subjects at risk of colorectal cancer [J]. Cancer Epidemiol Biomarkers Prey, 2015, 24(3):621-626. DOI: 10.1158/1055-9965.EPI-13-1281.
  • 10Xu CH, Yu LK, Hao KK. Serum YKL-40 level is associated with the chemotherapy response and prognosis of patients with small cell lung cancer[J]. PLoS One, 2014, 9(5):e96384. DOh 10.1371/journal.pone.0096384.

引证文献6

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部